Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.08. The business had revenue of $2.31 million for the quarter, compared to analyst estimates of $1.98 million. During the same period in the prior year, the firm earned ($0.23) earnings per share. View Synergy Pharmaceuticals' Earnings History.

10 brokers have issued twelve-month target prices for Synergy Pharmaceuticals' stock. Their forecasts range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $8.90 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (9/13/2017)
• 2. HC Wainwright analysts commented, "We note that the launch of Trulance appears to be progressing on multiple fronts, with the company having reached 66% of its targeted prescriber base and over 90% of the high-volume prescribers (deciles 8-10). According to QuintilesIMS data, as of mid-2017 over 12,600 Trulance prescriptions had been filled and total monthly prescription volume has increased on average over 182% month-over-month during that period. Over 32% of all high prescribers had written a Trulance prescription since the drug was launched earlier this year, with an average increase for all prescribers of approximately 140% month-over-month. Trulance achieved 6.8% new-to-brand prescription (NBRx) total market share and 12% NBRx market share among gastroenterologists. Importantly, about 55% of new Trulance prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment and 45% were patients who converted from other branded prescription treatments." (8/10/2017)
• 3. Cantor Fitzgerald analysts commented, "Management upbeat about early returns. SGYP reported 2Q17 results and posted a new corporate presentation to provide an update of the Trulance launch (here). We spoke with management (no results call was held) to hear its views regarding how the launch is proceeding. Acknowledging the inherent positive bias of company managements that have launched their inaugural product, we believe metrics provided by SGYP may, however, show an objective snapshot of the launch." (8/10/2017)

Synergy Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 67,570,644 shares, an increase of 6.8% from the August 15th total of 63,271,755 shares. Based on an average daily volume of 2,888,418 shares, the days-to-cover ratio is presently 23.4 days. Approximately 30.1% of the company's stock are sold short.

Some companies that are related to Synergy Pharmaceuticals include Dynavax Technologies Corporation (DVAX), Sangamo Therapeutics (SGMO), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER), Five Prime Therapeutics (FPRX), Athenex (ATNX), Epizyme (EPZM), Amarin Corporation PLC (AMRN), Retrophin (RTRX), ZIOPHARM Oncology (ZIOP), REGENXBIO (RGNX), Intra-Cellular Therapies (ITCI), Keryx Biopharmaceuticals (KERX) and Vanda Pharmaceuticals (VNDA).

Synergy Pharmaceuticals' management team includes the folowing people:

• Gary S. Jacob Ph.D., Chairman of the Board, President, Chief Executive Officer
• Gary G. Gemignani, Chief Financial Officer, Executive Vice President
• Marino Garcia, Executive Vice President, Chief Strategy Officer
• Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer
• Troy Hamilton, Executive Vice President, Chief Commercial Officer
• Melvin K. Spigelman M.D., Lead Independent Director
• Thomas H. Adams Jr. Ph.D., Independent Director
• John P. Brancaccio CPA, Independent Director
• Timothy S. Callahan, Independent Director
• Richard J. Daly, Independent Director

Synergy Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.75%), State Street Corp (5.75%), Northern Trust Corp (1.25%), TimesSquare Capital Management LLC (1.14%), Pictet Asset Management Ltd. (0.89%) and JPMorgan Chase & Co. (0.88%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., TIAA CREF Investment Management LLC, Palisade Capital Management LLC NJ, Bank of New York Mellon Corp, Cambridge Investment Research Advisors Inc., D.A. Davidson & CO. and State Treasurer State of Michigan. View Insider Buying and Selling for Synergy Pharmaceuticals.

Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., OxFORD Asset Management LLP, JPMorgan Chase & Co., Northern Trust Corp, Hikari Power Ltd, State Street Corp, Virtu KCG Holdings LLC and Pictet Asset Management Ltd.. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $2.60.